Payment overview · 2025
General Payments
$463.16
26 reported records · 13 companies
Healthcare provider profile · identity verified
Stacey Wayne Mayeaux, MD
Allopathic & Osteopathic Physicians|Internal Medicine · OPELOUSAS, LA · NPI 1013986892
Verified facts
What the public records show
CMS Open Payments records show Stacey Wayne Mayeaux, MD received $463.16 in general payments during 2025 across 26 reported records.
Ardelyx, Inc. accounted for 16.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Ozempic, Rybelsus, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $77.01 | 16.6% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $66.62 | 14.4% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $58.02 | 12.5% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $55.96 | 12.1% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $37.04 | 8.0% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $33.59 | 7.2% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $32.13 | 6.9% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $22.63 | 4.9% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $18.49 | 4.0% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.17 | 3.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.43 | 3.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.16 | 3.3% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $13.91 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $463.16 | 26 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $82.05 | 5 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $77.01 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $58.02 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $37.04 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $36.94 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $36.44 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $33.59 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $22.63 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $19.52 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $18.49 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $17.17 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $15.16 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.18 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.18 | 1 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $13.91 | 1 | 2025 |
Source payment records
|
|||||
| TRULANCE Normalized: trulance |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $13.91 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 125 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 66 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
66 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
125 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 675 | 138 |
| Amlodipine Besylate | Amlodipine Besylate | 577 | 116 |
| Levothyroxine Sodium | Levothyroxine Sodium | 574 | 92 |
| Montelukast Sodium | Montelukast Sodium | 558 | 107 |
| Omeprazole | Omeprazole | 554 | 99 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 496 | 85 |
| Gabapentin | Gabapentin | 491 | 75 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 452 | 70 |
| Carvedilol | Carvedilol | 442 | 90 |
| Lisinopril | Lisinopril | 421 | 87 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 356 | 70 |
| Furosemide | Furosemide | 352 | 42 |
| Trazodone Hcl | Trazodone Hcl | 322 | 51 |
| Pantoprazole Sodium | Pantoprazole Sodium | 310 | 44 |
| Fluticasone Propionate | Fluticasone Propionate | 306 | 90 |
| Metformin Hcl | Metformin Hcl | 302 | 65 |
| Meloxicam | Meloxicam | 291 | 72 |
| Hydrochlorothiazide | Hydrochlorothiazide | 265 | 54 |
| Buspirone Hcl | Buspirone Hcl | 263 | 32 |
| Alendronate Sodium | Alendronate Sodium | 245 | 53 |
| Tramadol Hcl | Tramadol Hcl | 239 | 52 |
| Sertraline Hcl | Sertraline Hcl | 235 | 34 |
| Glimepiride | Glimepiride | 225 | 41 |
| Fenofibrate | Fenofibrate Nanocrystallized | 215 | 40 |
| Duloxetine Hcl | Duloxetine Hcl | 207 | 27 |
| Alprazolam | Alprazolam | 205 | 33 |
| Losartan Potassium | Losartan Potassium | 197 | 40 |
| Zolpidem Tartrate | Zolpidem Tartrate | 193 | 30 |
| Lovastatin | Lovastatin | 192 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 189 | 25 |
| Potassium Chloride | Potassium Chloride | 180 | 36 |
| Allopurinol | Allopurinol | 172 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 167 | 60 |
| Mirtazapine | Mirtazapine | 165 | 21 |
| Donepezil Hcl | Donepezil Hcl | 152 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 146 | 37 |
| Pioglitazone Hcl | Pioglitazone Hcl | 146 | 29 |
| Ezetimibe | Ezetimibe | 141 | 34 |
| Levofloxacin | Levofloxacin | 140 | 103 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 139 | 27 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 133 | 22 |
| Simvastatin | Simvastatin | 128 | 24 |
| Methylprednisolone | Methylprednisolone | 127 | 99 |
| Eliquis | Apixaban | 125 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 124 | 22 |
| Sucralfate | Sucralfate | 124 | 26 |
| Tizanidine Hcl | Tizanidine Hcl | 123 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 122 | 23 |
| Metoprolol Succinate | Metoprolol Succinate | 115 | 26 |
| Valsartan | Valsartan | 114 | 20 |
| Nifedipine Er | Nifedipine | 113 | 18 |
| Famotidine | Famotidine | 112 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 109 | 20 |
| Metformin Hcl Er | Metformin Hcl | 109 | 17 |
| Clonidine Hcl | Clonidine Hcl | 101 | 17 |
| Januvia | Sitagliptin Phosphate | 100 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 97 | 15 |
| Pregabalin | Pregabalin | 97 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 96 | 14 |
| Memantine Hcl | Memantine Hcl | 90 | suppressed |
| Movantik | Naloxegol Oxalate | 88 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 87 | 16 |
| Nabumetone | Nabumetone | 87 | 19 |
| Diazepam | Diazepam | 84 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 82 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 80 | 13 |
| Prednisone | Prednisone | 80 | 53 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 79 | 12 |
| Celecoxib | Celecoxib | 76 | 18 |
| Glipizide | Glipizide | 74 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 73 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 72 | 55 |
| Clonazepam | Clonazepam | 71 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 69 | 13 |
| Benazepril Hcl | Benazepril Hcl | 68 | 12 |
| Ozempic | Semaglutide | 66 | 15 |
| Glipizide Er | Glipizide | 63 | suppressed |
| Lorazepam | Lorazepam | 63 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 61 | 15 |
| Baclofen | Baclofen | 61 | suppressed |
| Estradiol | Estradiol | 60 | 12 |
| Bupropion Hcl | Bupropion Hcl | 58 | 13 |
| Cefuroxime | Cefuroxime Axetil | 57 | 48 |
| Levetiracetam | Levetiracetam | 56 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 56 | 38 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 56 | 16 |
| Metoclopramide Hcl | Metoclopramide Hcl | 55 | suppressed |
| Zaleplon | Zaleplon | 55 | 12 |
| Clindamycin Hcl | Clindamycin Hcl | 52 | 45 |
| Azithromycin | Azithromycin | 51 | 48 |
| Fluoxetine Hcl | Fluoxetine Hcl | 51 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 51 | 13 |
| Gemfibrozil | Gemfibrozil | 49 | 11 |
| Linzess | Linaclotide | 49 | 13 |
| Spironolactone | Spironolactone | 49 | suppressed |
| Acarbose | Acarbose | 48 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 48 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 48 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 48 | suppressed |
| Amoxicillin | Amoxicillin | 46 | 39 |
| Finasteride | Finasteride | 45 | suppressed |
| Mounjaro | Tirzepatide | 45 | suppressed |
| Ondansetron Odt | Ondansetron | 45 | 24 |
| Synthroid | Levothyroxine Sodium | 43 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 40 | suppressed |
| Acyclovir | Acyclovir | 39 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 38 | 13 |
| Doxazosin Mesylate | Doxazosin Mesylate | 37 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 37 | suppressed |
| Methocarbamol | Methocarbamol | 37 | 11 |
| Olanzapine | Olanzapine | 37 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 36 | 21 |
| Ondansetron Hcl | Ondansetron Hcl | 36 | 17 |
| Sumatriptan Succinate | Sumatriptan Succinate | 36 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 35 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 34 | suppressed |
| Jardiance | Empagliflozin | 33 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 33 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 32 | suppressed |
| Rybelsus | Semaglutide | 32 | suppressed |
| Topiramate | Topiramate | 32 | suppressed |
| Xarelto | Rivaroxaban | 30 | suppressed |
| Levemir | Insulin Detemir | 29 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 29 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 28 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 28 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 28 | suppressed |
| Chlorthalidone | Chlorthalidone | 27 | suppressed |
| Aripiprazole | Aripiprazole | 26 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 26 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 23 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 25 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 25 | suppressed |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 25 | suppressed |
| Risperidone | Risperidone | 25 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 25 | suppressed |
| Lansoprazole | Lansoprazole | 24 | suppressed |
| Nystatin | Nystatin | 24 | 17 |
| Ranolazine Er | Ranolazine | 24 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 24 | 12 |
| Verapamil Er | Verapamil Hcl | 24 | suppressed |
| Methotrexate | Methotrexate Sodium | 23 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 22 | 15 |
| Colesevelam Hcl | Colesevelam Hcl | 22 | suppressed |
| Ibuprofen | Ibuprofen | 22 | 11 |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 22 | suppressed |
| Metronidazole | Metronidazole | 22 | 18 |
| Tradjenta | Linagliptin | 22 | suppressed |
| Fluconazole | Fluconazole | 21 | 19 |
| Naproxen | Naproxen | 21 | suppressed |
| Premarin | Estrogens, Conjugated | 21 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | 14 |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 20 | suppressed |
| Rexulti | Brexpiprazole | 20 | suppressed |
| Sotalol | Sotalol Hcl | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 18 |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Felodipine Er | Felodipine | 19 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 18 | suppressed |
| Humulin R | Insulin Regular, Human | 18 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 18 | suppressed |
| Lamotrigine | Lamotrigine | 18 | suppressed |
| Mupirocin | Mupirocin | 18 | 11 |
| Terazosin Hcl | Terazosin Hcl | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Atenolol | Atenolol | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | suppressed |
| Methimazole | Methimazole | 17 | suppressed |
| Niacin Er | Niacin | 17 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 17 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 15 | suppressed |
| Levemir Flexpen | Insulin Detemir | 15 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 15 | suppressed |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Euthyrox | Levothyroxine Sodium | 14 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 14 | suppressed |
| Vascepa | Icosapent Ethyl | 14 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 13 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 13 | suppressed |
| Ibu | Ibuprofen | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Cozaar | Losartan Potassium | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Febuxostat | Febuxostat | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| M-Natal Plus | Pnv,calcium 72/Iron/Folic Acid | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Savella | Milnacipran Hcl | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Aliskiren | Aliskiren Hemifumarate | 11 | suppressed |
| Armodafinil | Armodafinil | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Clonidine | Clonidine | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 11 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 11 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 11 | suppressed |
| Trueplus Insulin Syringe | Syringe And Needle,insulin,1ml | 11 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $463.16 · 26 records | Ardelyx, Inc. | AIRSUPRA, Auvelity, BREZTRI, Cologuard Collection Kit, ELIQUIS, IBSRELA, JARDIANCE, Korlym, NURTEC ODT, Ozempic, RELISTOR, Rybelsus, TRELEGY ELLIPTA, TRULANCE, VOQUEZNA, ZORYVE | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error